Neuropsychiatric Disease and Treatment · 2008 · 109 citations · 22 references
MedicinePharmacologyPharmacotherapyBioavailabilityClinical PharmacologyNeuropharmacologyDopaminergic PharmacologyNeurodegenerative Disease PharmacologyNeurodegenerative Disease PharmacotherapyParkinson DiseaseParkinsonian DisordersDopaminergic Therapy ManagementDose Fractionation EffectsDose Fractionation OptimizationDose Fractionation RegimensEmergenceParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease Treatment
After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson's disease (PD) despite the recent emergence of a host of new therapies. Some physicians are cautious when prescribing levodopa because of its association with motor complications. Evidence now suggests that levodopa-associated complications are a result of deep troughs in delivery of levodopa to the brain caused by the short plasma half-life of conventional levodopa formulations (levodopa and a dopa decarboxylase inhibitor [DDCI]). Dosing strategies, such as dose increases and dose fractionation, may be effective in the short term. For the longer-term, levodopa/carbidopa/entacapone provides pharmacokinetically optimized levodopa therapy that significantly increases the plasma half-life and bioavailability of levodopa, providing more consistent plasma levodopa levels without deep troughs. Evidence from clinical trials in PD patients experiencing re-emergence of symptoms due to wearing-off has consistently shown that levodopa/DDCI and entacapone significantly increases ON-time and affords greater functionality, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) with conventional levodopa. These trials have also shown that levodopa/DDCI and entacapone is generally well tolerated, with notable adverse events including worsening dyskinesia, nausea and diarrhea. Patients experiencing re-emergence of symptoms due to wearing-off may benefit from optimized levodopa therapy with levodopa/carbidopa/entacapone.
22
Olivier Rascol, David J. Brooks, Amos D. Korczyn et al. · New England Journal of Medicine · 2000 · 1.5K citations · Full text
Medicine, Neurology, Pharmacotherapy +11
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Irene Litvan, Kailash P. Bhatia, David J. Burn et al. · Movement Disorders · 2003 · 1K citations
Medicine, Neurology, Neuroscience +17
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Robert G. Holloway, Ira Shoulson, Karl Kieburtz et al. · JAMA · 2000 · 802 citations
Medicine, Neurology, Pharmacotherapy +12
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE
C. D. Marsden, J. D. Parkes · The Lancet · 1977 · 590 citations
Medicine, Neurology, Pharmacotherapy +10
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
Archives of Neurology · 2004 · 562 citations · Full text